Search Result

Results for "

Alpha-Synuclein Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (16) Amyloid-β (4) Apoptosis (1) Autophagy (1) Beclin1 (1) Cholinesterase (ChE) (1) DNA/RNA Synthesis (2) DYRK (2) Endogenous Metabolite (1) Huntingtin (1) Necroptosis (1) RIP kinase (1) Sirtuin (1)
By Research Areas:	Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (28)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: α-synuclein 5 alpha Reductase IFNAR PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145580

Minzasolmin

UCB0599; (R)-NPT200-11
α-synuclein Neurological Disease

Minzasolmin is an alpha-synuclein oligomerization inhibitor .

Minzasolmin UCB0599; (R)-NPT200-11	α-synuclein	Neurological Disease
Minzasolmin is an alpha-synuclein oligomerization inhibitor .

HY-125287

(Rac)-Minzasolmin (Rac)-UCB0599; NPT200-11	α-synuclein	Neurological Disease
(Rac)-Minzasolmin ((Rac)-UCB0599) is a brain penetrating inhibitor of accumulation of *alpha-synuclein* (ASYN) misfolding and aggregation. (Rac)-Minzasolmin can be used for research of Parkinson's disease .

HY-119857

AGK7 SIRT2 Inhibitor,Inactive Control	Sirtuin	Neurological Disease
AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .

HY-149509

*α-Synuclein* inhibitor 9**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an *α-Synuclein* inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

HY-152552

*α-Synuclein* inhibitor 8**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 8 is an active inhibitor of *α-Synuclein* with an IC₅₀ value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .

HY-147644

*α-Synuclein* inhibitor 3**	Others	Neurological Disease
α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .

HY-144696

Dyrk1A/α-synuclein-IN-2	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-156435

tau protein/α-synuclein-IN-1	α-synuclein	Neurological Disease
tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and *α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein*-IN-1 can be used in study Alzheimer’s disease .

HY-163145

*α-Synuclein* inhibitor 11**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .

HY-157806

*α-Synuclein* inhibitor 12**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of *α-Syn* (α-synuclein) aggregation and can be used in the study of neurological diseases .

HY-157308

*α-Synuclein* inhibitor 10**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

HY-144695

Dyrk1A/α-synuclein-IN-1	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

HY-147669

*α-Synuclein* inhibitor 7**	Others	Neurological Disease
α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.95 μM and inhibition ratio at 30 μM of 85.8% .

HY-147666

*α-Synuclein* inhibitor 4**	Others	Neurological Disease
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 0.98 μM and inhibition ratio at 30 μM of 91.2% .

HY-147667

*α-Synuclein* inhibitor 5**	Others	Neurological Disease
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.22 μM and inhibition ratio at 30 μM of 94.3% .

HY-147668

*α-Synuclein* inhibitor 6**	Others	Neurological Disease
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of **α-Synuclein (α-Syn) aggregation, with an IC₅₀** of 1.70 μM and inhibition ratio at 30 μM of 94.4% .

HY-145580A

(S)-Minzasolmin

(S)-UCB0599; (S)-NPT200-11
α-synuclein Neurological Disease

(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

(S)-Minzasolmin (S)-UCB0599; (S)-NPT200-11	α-synuclein	Neurological Disease
(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

HY-157225

Brazilin-7-acetate	α-synuclein	Metabolic Disease
Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .

HY-135902

Synucleozid NSC 377363	DNA/RNA Synthesis	Neurological Disease
Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the *α-synuclein* mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-135902A

Synucleozid hydrochloride NSC 377363 hydrochloride	DNA/RNA Synthesis	Neurological Disease
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the α-synuclein mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-120475

PBT434 ATH434	α-synuclein	Neurological Disease
PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .

HY-120475A

PBT434 mesylate ATH434 mesylate	α-synuclein	Neurological Disease
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .

HY-124876

SynuClean-D SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of *α-synuclein* aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .

HY-153416

QR-0217	Amyloid-β	Neurological Disease
QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC₅₀ value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .

HY-16009

Buntanetap (+)-Phenserine; ANVS401	Cholinesterase (ChE) Amyloid-β α-synuclein Huntingtin	Neurological Disease Inflammation/Immunology
Buntanetap ((+)-Phenserine) is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Neurological Disease
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-134050

Apostatin-1 Apt-1	RIP kinase Autophagy Apoptosis Beclin1 Necroptosis	Inflammation/Immunology
Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (K_D=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of RIPK1 and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin .

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

Scyllo-Inositol	Structural Classification Natural Products Source classification Endogenous metabolite	Amyloid-β Endogenous Metabolite
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

Peucedanocoumarin III	Structural Classification Source classification Isodon yuennanensis (Handel-Mazzetti) H. Hara Coumarins Phenylpropanoids Plants Umbelliferae	α-synuclein
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Alpha-Synuclein Inhibitors

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products